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BACKGROUND: Patient selection for addition of anti-EGFR therapy to chemotherapy for patients with RAS and BRAF wildtype
metastatic colorectal cancer can still be optimised. Here we investigate the effect of anti-EGFR therapy on survival in different
consensus molecular subtypes (CMSs) and stratified by primary tumour location.
METHODS: Retrospective analyses, using the immunohistochemistry-based CMS classifier, were performed in the COIN (first-line
oxaliplatin backbone with or without cetuximab) and PICCOLO trial (second-line irinotecan with or without panitumumab). Tumour
tissue was available for 323 patients (20%) and 349 (41%), respectively.
RESULTS: When using an irinotecan backbone, anti-EGFR therapy is effective in both CMS2/3 and CMS4 in left-sided primary
tumours (progression-free survival (PFS): HR 0.44, 95% CI 0.26–0.75, P= 0.003 and HR 0.12, 95% CI 0.04–0.36, P < 0.001, respectively)
and in CMS4 right-sided tumours (PFS HR 0.17, 95% CI 0.04–0.71, P= 0.02). Efficacy using an oxaliplatin backbone was restricted to
left-sided CMS2/3 tumours (HR 0.57, 95% CI 0.36–0.96, P= 0.034).
CONCLUSIONS: The subtype-specific efficacy of anti-EGFR therapy is dependent on the chemotherapy backbone. This may provide
the possibility of subtype-specific treatment strategies for a more optimal use of anti-EGFR therapy.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01477-9
INTRODUCTION
Since the introduction of targeted agents, anti-VEGF and anti-
EGFR therapy have become part of the standard treatment arsenal
for patients with metastatic colorectal cancer (mCRC). Anti-EGFR
agents (cetuximab, panitumumab) may be given as monotherapy
in chemorefractory patients, but are usually combined in earlier
lines (first or second line) with chemotherapy, with either an
oxaliplatin or irinotecan backbone, which are both considered
effective and safe regimens [1, 2].
The efficacy of anti-EGFR therapy was shown to be restricted to
the subgroup of patients with RAS or BRAFV600E wildtype
tumours, as no benefit was observed in patients with tumours
that harbour these mutations [3, 4]. Anti-EGFR therapy was even
associated with a detrimental effect in patients with KRAS mutant
tumours [5–7]. Patient selection for anti-EGFR therapy was further
improved by taking into account the sidedness of the primary
tumour, since patients with right-sided primary tumours do not
benefit from the addition of anti-EGFR to chemotherapy [8].
However, more recent data caution against the absolute use of
this criterion [9, 10]. This stresses the need for further stratification
and patient selection beyond RAS/BRAF mutations and tumour
sidedness.
Recent work on molecular subtyping has demonstrated its
predictive value for anti-EGFR therapies, and thus diagnostic utility
in optimising selection criteria. The consensus molecular subtypes
(CMSs) capture the biological heterogeneity in colorectal cancer
by recognising four distinct subtypes [11]: with CMS1 charac-
terised by microsatellite instability, strong immune activation and
BRAF-mutations; CMS2 is an epithelial subtype with high
chromosomal instability and prominent WNT and MYC signalling
activation; CMS3 is also an epithelial subtype with metabolic
dysregulation and is enriched for KRAS-mutations; and CMS4
represents a mesenchymal subtype with marked TGF-β activation
and abundant stromal content. Whilst patients with epithelial
CMS2/3 tumours benefit from anti-EGFR agents given as mono-
therapy or combined with an oxaliplatin-based chemotherapy
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regimen [12–14], patients with CMS4 tumours appear to have no
or even a detrimental effect when anti-EGFR is added to an
oxaliplatin-based regimen [13, 14]. In contrast, patients with
mesenchymal CMS4 mCRC have a significant survival benefit
when anti-EGFR is added to FOLFIRI, whereas for patients with
CMS2 tumours no such benefit was seen [15]. An analysis on the
differences between the CALB/SWOG 80405 and FIRE-3 studies
also suggested that cetuximab activity is synergistic with
irinotecan in all CMS subgroups, and with oxaliplatin only in
CMS2 and CMS3 [16]. Based on these studies we hypothesised
that anti-EGFR therapy has a subtype specific effect, which is
dependent on the chemotherapy backbone used.
To further investigate the possible differential effect of
backbone regimens in combination with anti-EGFR therapy for
the different molecular subtypes we stratified patients enrolled
in two prospective clinical trials, the COIN and the PICCOLO trials
[17, 18]. The treatment effects of either a first-line oxaliplatin-
based (COIN trial) or a second-line irinotecan backbone
(PICCOLO trial) on anti-EGFR activity stratified by CMSs were
studied. We hypothesised that anti-EGFR treatment is most
effective when added to an oxaliplatin backbone in patients
with CMS2/3 tumours in the COIN trial, while patients with
mesenchymal CMS4 benefit most from anti-EGFR added to an
irinotecan backbone as given in the PICCOLO trial. Furthermore,
we performed exploratory analyses into differing effects




Details on both trial protocols have been previously reported [17, 18]. In
short, the randomised controlled, multicenter, COIN trial was conducted
between 2005 and 2008. Patients without previous chemotherapy
for mCRC were randomly assigned to oxaliplatin and fluoropyrimidine
chemotherapy (CAPOX (capecitabine and oxaliplatin) or FOLFOX
(5-fluorouracil and oxaliplatin)), the same combination plus cetuximab,
or intermittent chemotherapy. No selection based on mutation status
was done.
The PICCOLO trial was a multicenter, randomised controlled trial in the
second-line treatment of mCRC. Patients were included between 2006
and 2010 to a three-arm design of second-line therapy of irinotecan,
irinotecan plus ciclosporin and irinotecan plus panitumumab. From June
10, 2008 panitumumab randomisation was restricted to patients with
KRASc.12,13,61 wildtype tumours.
Primary endpoint of both studies was overall survival (OS), with
secondary endpoints of progression-free survival (PFS), tumour response
(RECIST) and toxicity. For current analyses, only RAS (for both trials:
KRASc.12,13,61 and NRASc.12,61, additional for the PICCOLO trial: KRASc.146
and NRASc.13) and BRAFc.600 wildtype patients of the CAPOX/FOLFOX and
CAPOX/FOLFOX with cetuximab treatment arms from the COIN trial and
irinotecan and irinotecan with panitumumab arm from the PICCOLO trial
were included.
Right-sided primary tumours were defined as tumours located proximal
from the splenic flexure, left-sided tumours as tumours arising in or distal
from the splenic flexure.
CMS Classification
Tumour tissue from the primary tumour was collected for both trials from all
available patients. For each primary tumour three or four cores were available
on a tissue microarray (TMA) on a 4-µm-thick section slide. Tumours were
stratified into the different consensus molecular subtypes using the
previously developed immunohistochemistry (IHC)-based classifier [14, 19].
CMS1 patients were first classified using mismatch repair (MMR) protein
expression status, identified by IHC of four markers (MLH1, MSH2, MSH6 and
PMS2). Tumours with loss of expression of one of these markers were
considered MMR deficient. Next, TMA slides were stained for five markers
(CDX2, FRMD6, HTR2B, ZEB1 and KER) and classified into epithelial (CMS2/3)
or mesenchymal subtype (CMS4) using the published image analysis pipeline
and CMS-IHC classifier [14]. A probability of >60% was used for a core to be
classified as mesenchymal, and a tumour was classified as CMS4 if at least
one core was identified as mesenchymal.
Statistical analysis
Stata version 15 was used for statistical analyses. Baseline patient
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Fig. 1 Study flow diagram. Overview of included samples for the COIN trial (a) and PICCOLO trial (b). CAPOX, capecitabine and oxaliplatin;
FOLFOX, 5-fluorouracil and oxaliplatin.
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Pearson Chi-squared tests for categorical variables where the count was >5
in a cell and Fishers exact tests otherwise. Kruskal–Wallis tests were used
for continuous variables. For calculation of P-values, unknowns were
excluded.
Time-to-event curves for PFS and OS were calculated using the
Kaplan–Meier method. Hazard ratios (HRs), 95% confidence intervals (CIs)
and P-values were estimated using cox proportional Hazards models.
Response data were compared between treatment groups using logistic
regression and estimating odds ratios (ORs). All presented HRs and ORs for
the main and sensitivity analysis are adjusted for age, sex and WHO
performance status. P-values were two-sided and an arbitrary 5% cut-off
was used for statistical significance. R software version 4.0.5 was used for P-
value multiple testing correction using the Benjamini-Hochberg procedure,
with an alpha of 0.05 [20]. We corrected P-values per independent analysis,
i.e., for the total cohorts, left-sided and right-sided tumours. Adjusted P-
values are indicated in the figure legends.
RESULTS
Patient characteristics
Of 1630 COIN trial patients enrolled in the treatment arms of
interest, tumour tissue for CMS classification was available for 323
patients (19.8%), of which 140 (43.3%) were RAS and BRAF
wildtype. For the PICCOLO trial, of 861 patients enrolled in the
treatment arms of interest for 349 (40.5%) tumour tissue was
available for classification with 163 (46.7%) being RAS and BRAF
wildtype (Fig. 1). All patients with tumour tissue available were
classified into either CMS2/3 or CMS4 using a previously
developed and validated immunohistochemical assay [14, 19].
For both cohorts the classified samples were representative for the
total study population, but had improved PFS and OS (non-
significant) with a higher proportion of resected primary tumours
(Supplementary Table 1). This is inherently linked to the method
of CMS classification used, as this requires sufficient tumour tissue
for staining. In the RAS and BRAF wildtype cohort, the treatment
arms were well balanced, apart from the primary tumour location
in the PICCOLO trial, in which case the proportion of right-sided
tumours was higher in the control (irinotecan) arm (Supplemen-
tary Table 2).
CMS classification
In the classified wildtype cohort, 37% (52/140 COIN) and 31% (51/
163 PICCOLO) of patients were classified as CMS4 (Table 1). CMS1
was excluded in the analysis due to low numbers in both cohorts
(n= 4 and n= 2), in line with the notion that MMR deficient
cancers are rare in mCRC [21]. Patients with CMS4 cancers were
younger compared to CMS2/3 in the COIN trial (mean age 60.8
(SD= 10.2) versus 64.9 (SD= 8.4), P= 0.037), and CMS2/3 cancers
were more frequently left-sided in the PICCOLO trial (45% versus
27%, P= 0.04) (Table 1). In the COIN trial CMS2/3 patients have a
(non-significant) longer overall survival (22.3 versus 15.7 months,
P= 0.07) compared to CMS4, for the PICCOLO trial on second-line
anti-EGFR therapy there was no difference in survival between
the epithelial and mesenchymal subtypes.
Efficacy of anti-EGFR in CMS subtypes
When assessing the treatment response in the RAS and
BRAF wildtype cohort there was a clear difference in response
to anti-EGFR for the CMS4 tumours between both trials. When
added to irinotecan there was a significantly longer PFS in CMS4
(HR 0.26, 95% CI 0.13–0.52, P < 0.001) (Fig. 2a), but when added
to CAPOX/FOLFOX there was no beneficial effect of the addition
of cetuximab (HR 1.68, 95% CI 0.91–3.10, P= 0.10) (Fig. 2b). For
CMS2/3 patients there was also a (non-significant) benefit for
anti-EGFR addition to irinotecan in the PICCOLO trial (HR 0.67,
95% CI 0.44–1.01, P= 0.06) (Fig. 2c), and a (non-significant)
PFS benefit when added to CAPOX/FOLFOX in the COIN trial
(HR 0.69, 95% CI 0.43–1.11, P= 0.12) (Fig. 2d). No difference in
OS was observed.
As the combination of capecitabine-based chemotherapy and
cetuximab was shown to be more toxic and, therefore, less
effective compared to 5-fluorouracil-based chemotherapy and
cetuximab [17, 22, 23], a sensitivity analysis for the COIN trial with
patients receiving either CAPOX or FOLFOX was performed.
Among wildtype patients, 63% (n= 86) was treated with either
CAPOX or the combination of CAPOX with cetuximab. For CMS2/3
patients there was indeed a better outcome when cetuximab was
added to FOLFOX, though this was not significant (PFS HR 0.45,
95% CI 0.17–1.20, P= 0.11; OS HR 0.48, 95% CI 0.17–1.31, P= 0.15)
(Supplementary Fig. 1A).
Analysis of the response data convey comparable results, with
response only observed in CMS4 when panitumumab was
added to irinotecan (OR 8.52, 95% CI 1.69–43.05, P= 0.01)
(Table 2). In CMS2/3 there was also a significantly better
response when panitumumab was added to irinotecan (OR 4.27,
95% CI 1.66–11.00, P= 0.003), no difference was observed to the
addition of cetuximab to CAPOX/FOLFOX (OR 1.72, 95% CI
0.60–4.95, P= 0.31).
Effect of primary tumour location
In the combined RAS and BRAF wildtype cohort the majority of the
tumours were left-sided (75%; COIN: 81% and PICCOLO: 69%). The
distribution of the CMSs was similar in both trials and there was no
difference between left- and right-sided tumours ((Left: CMS2/3
65%, CMS4 35%; Right: CMS2/3: 64%, CMS4: 36%; X2= 0.077, P=
0.78) (Supplementary Table 3).
In left-sided tumours, a clear difference between the subtypes
in efficacy of anti-EGFR with the different backbones was
observed, with CMS2/3 having a significant PFS benefit from the
addition of anti-EGFR with both chemotherapy backbones
(CAPOX/FOLFOX HR 0.57, 95% CI 0.36–0.96, P= 0.034; Irinotecan
HR 0.44, 95% CI 0.26–0.75, P= 0.003). In CMS4 there was only a
significant PFS benefit for anti-EGFR when added to irinotecan
(HR 0.12, 95% CI 0.04–0.36, P < 0.001). When anti-EGFR was
added to CAPOX/FOLFOX in CMS4 tumours even a detrimental
effect was seen (HR 2.76, 95% CI 1.27–6.01, P= 0.006) (Fig. 3 and
Supplementary Fig. 1B).
For right-sided tumours a significant PFS and OS benefit was
observed for CMS4 tumours when anti-EGFR was added to
irinotecan as second line chemotherapy for both PFS (HR 0.17,
95% CI 0.04–0.71, P= 0.02) and OS (HR 0.20, 95% CI 0.05–0.83,
P= 0.03) (Fig. 4 and Supplementary Fig. 1C). No benefit of anti-
EGFR was observed in right-sided CMS2/3 tumours. A summary
of our results with possible implications for treatment recom-
mendations based on the CMSs and tumour sidedness is shown
in Supplementary Fig. 2.
DISCUSSION
In this retrospective study of two trial cohorts, we show a
differential effect of anti-EGFR therapy in the main CMS subtypes
when combined with different chemotherapy backbones. The
largest benefit of anti-EGFR was observed in patients with
mesenchymal CMS4 tumours when combined with an irinotecan
backbone. This effect was seen in both left and right-sided primary
tumours. For epithelial CMS2/3 tumours there was a benefit from
the addition of anti-EGFR when added to both oxaliplatin and
irinotecan-based chemotherapy, which was only observed in left-
sided primary tumours.
Our results are in line with others, who showed a PFS and OS
survival benefit effect from anti-EGFR for CMS4 when added to
an irinotecan-based first-line treatment regimen [15, 16]. The
high disease control rate in CMS4 but also in CMS2 when anti-
EGFR is combined with irinotecan was also shown in a recent
publication, 93.3% and 76.9% for CMS2 and CMS4, respectively
[24]. The CALGB/SWOG 80405 study did not show a survival
difference for the addition of either bevacizumab or cetuximab
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to chemotherapy in CMS4 tumours [13]. Unfortunately, numbers
to perform separate analyses on patients receiving either a
FOLFOX or FOLFIRI chemotherapy backbone are relatively low.
Various clinical studies support the notion that the efficacy of
anti-EGFR antibodies is restricted to left-sided tumours [8, 25, 26].
However, a recently updated meta-analysis indicated that anti-
EGFR therapies could remain an option for patients with RAS
wildtype right-sided tumours, as this significantly improved PFS
and therapy response in both left- and right-sided tumours [9].
This finding is in line with the here reported results, which show
that patients with both left- and right-sided CMS4 tumours benefit
from the combination of irinotecan and panitumumab (Figs. 3 and
4). Therefore, anti-EGFR may potentially be considered in patients
with right-sided CMS4 tumours.
Several preclinical studies have shown a synergistic effect
between anti-EGFR therapy and irinotecan [27–29]. Tumour cell
exposure to irinotecan leads to resistance through upregulation of
EGFR signalling. Anti-EGFR overcomes this resistance through
downregulation of the EGFR pathway which is upregulated by
irinotecan [28, 30], explaining the benefit observed in irinotecan-
refractory mCRC [31]. Another proposed mechanism underlying
the enhanced tumour response of the combination of these two
agents is a cetuximab induced suppression of mammalian heat
shock protein 27 (HSP27), which is reported to be involved in
irinotecan resistance, through blocking the JAK/STAT signalling
pathway in RAS wildtype CRC cells [27].
There is some evidence that irinotecan-based regimens have a
higher overall response rate (ORR) and improved PFS when
Table 1. Baseline and survival characteristics for the molecular subtypes in RAS and BRAF wildtype cohort.










Agea (Mean (SD)) 64.9 (8.4) 60.8 (10.2) 0.04 62.7 (10.3) 62.6 (10.3) 0.96
Sex No. (%) Male 64 (76.2) 34 (65.4) 0.17 77 (70.0) 38 (74.5) 0.67
Female 20 (23.8) 18 (34.6) 31 (28.2) 13 (25.5)
Unknown 2 (1.8) 0 (0.0)
Performance status No. (%) 0 43 (51.2) 24 (46.2) 0.71 42 (38.2) 27 (53.9) 0.21
1 36 (42.9) 23 (44.2) 61 (55.4) 22 (43.1)
2 5 (6.0) 5 (9.6) 7 (6.4) 2 (3.9)
Primary tumour location No. (%) Right 15 (17.9) 11 (21.2) 0.19 32 (29.1) 16 (31.4) 0.04
Left 37 (44.0) 29 (55.8) 49 (44.6) 14 (27.4)
Rectum 32 (38.1) 12 (23.1) 25 (22.7) 21 (41.2)
Unknown 0 (0.0) 0 (0.0) 4 (3.6) 0 (0.0)
Resected primary No. (%) No 18 (21.4) 7 (13.5) 0.24 5 (4.6) 2 (3.9) 1.00
Yes 66 (78.6) 45 (86.5) 104 (94.5) 49 (96.1)
Unknown 0 (0.0) 0 (0.0) 1 (0.9) 0 (0)
Liver metastases No. (%) No 25 (29.8) 8 (15.4) 0.06 28 (25.5) 16 (31.4) 0.50
Yes 59 (70.2) 44 (84.6) 79 (71.8) 35 (68.6)
Unknown 0 (0.0) 0 (0.0) 3 (2.7) 0 (0.0)
Lung metastases No. (%) No 46 (54.8) 33 (63.5) 0.32 38 (34.6) 22 (43.1) 0.29
Yes 38 (45.2) 19 (36.5) 70 (63.6) 28 (54.9)
Unknown 0 (0.0) 0 (0.0) 2 (1.8) 1 (2.0)
Peritoneal metastases No. (%) No 75 (89.3) 46 (88.5) 0.88 84 (76.4) 41 (80.4) 0.87
Yes 9 (10.7) 6 (11.5) 22 (20.0) 10 (19.6)
Unknown 0 (0.0) 0 (0.0) 4 (3.6) 0 (0.0)
Number of metastatic sites No. (%) 0/1 35 (41.7) 22 (42.3) 0.94 26 (23.6) 18 (35.3) 0.15
2 or more 49 (58.3) 30 (57.7) 79 (71.8) 32 (62.7)
Unknown 0 (0.0) 0 (0.0) 5 (4.6) 1 (2.0)
Outcome
Overall survival (months) 22.3 15.7 0.07 13.2 12.7 0.26
Median (IQR) (10.8–39.8) (10.2–28.4) (7.2–20.0) (9.3–24.6)
Progression-free survival (months) 9.1 9 0.17 5.3 5.6 0.26
Median (IQR) (6.1–14.8) (5.3–12.7) (2.8–8.3) (2.8–9.3)
Best response No. (%) CR or PR 58 (69.0) 36 (69.2) 0.80 29 (26.4) 13 (25.5) 0.83
SD or PD 22 (26.2) 15 (28.8) 78 (70.9) 38 (74.5)
Unknown 4 (4.8) 1 (1.9) 3 (2.7) 0 (0.0)
aAge at randomisation (years). Pearson Chi-squared test used for categorical variables where the count was >5 in a cell and Fishers exact test used otherwise
Kruskal–Wallis test used for continuous variables. Unknowns were excluded for testing variables. Log-rank test was used for survival outcomes. CR or PR,
complete or partial response; N, number of SD or PD, patients; SD, standard deviation; stable disease or progressive disease.
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combined with anti-EGFR in comparison to the combination with
an oxaliplatin-based regimen [32, 33]. However, this may also be
explained by the negative interaction between capecitabine in
CAPOX regimens and anti-EGFR, as there is no difference in
effectiveness when comparing the addition of anti-EGFR to either
FOLFOX or FOLFIRI [22, 23].
Irinotecan-based treatment regimens, in general, appear to be
more effective in CMS4 tumours when compared to oxaliplatin-
based therapies [24, 34–36]. Moreover, preclinical studies in CMS4
cell lines and stem-like subtype tumours in patients, which are
related to CMS4, show a marked response to topoisomerase
inhibitors [37, 38]. However, the reason why mesenchymal
Table 2. Best responsea for subtype-specific anti-EGFR efficacy.
Trial Treatment CMS2/3 CMS4
CR or PR No. (%) OR (95% CI) P-value CR or PR No. (%) OR (95% CI) P-value
Yes No Yes No
COIN CAPOX/FOLFOX 23 (65.7) 12 (34.3) 1.00 0.31 19 (70.4) 8 (29.6) 1.00 0.95
CAPOX/FOLFOX 35 (77.8) 10 (22.2) 1.72 17 (70.8) 7 (29.2) 1.05
+ Cetuximab (0.60–4.95) (0.28–3.96)
PICCOLO Irinotecan 9 (15.5) 49 (84.5) 1.00 0.003 3 (10.7) 25 (89.3) 1.00 0.01
Irinotecan 20 (40.8) 29 (59.2) 4.27 10 (43.5) 13 (56.5) 8.52
+ Panitumumab (1.66–11.00) (1.69–43.05)
aBest response: CR/PR versus SD/PD/Death. Only deaths which occurred within 12 weeks were included. ORs are adjusted for age, sex and WHO performance
status. CAPOX, capecitabine and oxaliplatin (CAPOX/FOLFOX); CR, complete response; FOLFOX, 5-fluorouracil and oxaliplatin; OR, odds ratio; PR, partial
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Fig. 2 Molecular subtype-specific efficacy of anti-EGFR. Progression-free survival for CMS4 in the PICCOLO trial (a) and the COIN trial (b) and
for CMS2/3 in the PICCOLO trial (c) and the COIN trial (d). HRs are adjusted for age, sex and WHO performance status. CAPOX capecitabine and
oxaliplatin, FOLFOX 5-fluorouracil and oxaliplatin, HR hazard ratio. P-values adjusted for multiple testing: 0.12 (a), 0.10 (b), 0.12 (c), 0.004 (d).
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tumours seem to be more susceptible to an irinotecan-based
chemotherapy regimen is not yet understood. A possible
mechanism of the antagonistic action of oxaliplatin in combina-
tion with anti-EGFR could be the fibroblast rich tumour micro-
environment of CMS4 cancers, that increases the effects of
oxaliplatin induced cytokines, which might subsequently antag-
onise the antitumor effects of cetuximab and the cetuximab-
oxaliplatin synergy [16].
In the current study we show that patients with CMS2/3
tumours may benefit from anti-EGFR therapy combined with
either an irinotecan or oxaliplatin backbone. The effects seen in
the COIN trial were however small, which is likely explained by the
fact that the majority of patients in this study were treated with
CAPOX and cetuximab, notably this regimen is currently not
recommended for its increased toxicity and lack of efficacy
[17, 22, 23]. A sensitivity analysis showed a much better response
when cetuximab was added to FOLFOX as compared to CAPOX
(Supplementary Fig. 1A).
In both the COIN and PICCOLO trials a benefit of the addition
of anti-EGFR was seen only for PFS, but not for OS, with an
exception for the right-sided CMS4 tumours which benefited
from the addition of anti-EGFR to irinotecan in both PFS and OS.
The PFS is a direct measure of the treatment effect of the study,
while OS is the result of the cumulative survival after all the lines
of treatment that the patients underwent. Lack of overall
survival benefit in the COIN trial was attributed by the authors to
the combination of including patients with more advanced CRC
and the more toxic effects of the combination of CAPOX and
cetuximab [17]. For the FOLFOX treated patients we have indeed
shown a trend towards OS benefit when anti-EGFR is added
(Supplementary Fig. 1A). For the PICCOLO trial also only a PFS
benefit was detected for the wildtype cohort. An inferior survival
after relapse for the panitumumab treated patients was
observed, especially for the population with a mutation (either
KRAS, BRAF, NRAS or PIK3CA), possibly due to accelerated tumour
growth caused by the anti-EGFR therapy [18]. In this study,
however, we did see an OS benefit for the addition of anti-EGFR
to panitumumab in right-sided CMS4 patients (Supplementary
Fig. 1C).
We detected a trend towards OS benefit in CMS2/3 in the COIN
trial, and no difference in survival between CMS2/3 and CMS4 in
the PICCOLO trial. When looking at the total population, CMS4
confers the worst prognosis, because often these tumours present
at a higher stage [21]. In mCRC the difference in survival between
CMS2 and CMS4 is less pronounced, and worse survival is
described for CMS1 [11]. Although numbers of CMS1 were low in
this subpopulation, we did see indeed the lowest survival time for
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Fig. 3 Molecular subtype-specific efficacy of anti-EGFR in left-sided tumours. Progression-free survival in the COIN trial for CMS2/3 (a) and
CMS4 (b) and the PICCOLO trial for CMS2/3 (c) and CMS4 (d). HRs are adjusted for age, sex and WHO performance status. CAPOX capecitabine
and oxaliplatin, FOLFOX 5-fluorouracil and oxaliplatin, HR hazard ratio. P-values adjusted for multiple testing: 0.034 (a), 0.008 (b), 0.006 (c),
0.004 (d).
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It is important to mention that the CMS classification of both
studies was based on primary tumour tissue, which does not take
into account any potential subtype switch during progression of
disease, as well as the possible impact of chemotherapy on
changing tumour biology as we classified the primary tumours
pretreatment [39, 40].
Despite conducting this analysis on a smaller subcohort of the
original trial due to limitations in tissue availability for classification,
patient demographic characteristics and outcomes were consistent
with the main trial analyses. The small survival benefit in both
classified cohorts might be due to the higher number of resected
primary tumours, which may be associated with improved OS [41].
This study analysed small subgroups and was underpowered to
detect CMS/treatment interactions. Multiple comparisons were
made and borderline significant results should be interpreted with
caution. The retrospective nature of this study design and the cross-
study comparison does not allow for definitive conclusions about
the differential effect of the backbone therapy and anti-EGFR in the
different subtypes, especially due to the different lines of therapy
(first- versus second-line) which might contribute to the differences
found. Nonetheless, we evaluated these two studies with a specific
hypothesis in mind, which was confirmed by the result. This
positions the current study as a starting point in refining selection
criteria for anti-EGFR therapy based on CMS and primary tumour
location. Additional studies are warranted to validate these findings
and to reach definitive conclusions about the differential effect of
chemotherapy backbones in relation with CMSs for anti-EGFR
therapy. In addition, our study shows the potential clinical impact of
stratifying patients into CMSs. This supports our current effort to
implement the CMS classification into everyday clinical practice.
In conclusion, our results suggest that molecular subtypes may
play an important role in the effectiveness of the type of
chemotherapy backbone given in combination with anti-EGFR
therapy. There is some evidence that patients with RAS and BRAF
wildtype mesenchymal CMS4 tumours may only benefit when
anti-EGFR is combined with irinotecan, even in right-sided primary
tumours. For epithelial CMS2/3 tumours, we demonstrate no
difference between irinotecan- and oxaliplatin backbones for the
beneficial additive effect of anti-EGFR. This may provide the
possibility of subtype-specific treatment strategies for the optimal
use of anti-EGFR therapy.
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Fig. 4 Molecular subtype-specific efficacy of anti-EGFR in right-sided tumours. Progression-free survival in the COIN trial for CMS2/3 (a) and
CMS4 (b) and the PICCOLO trial for CMS2/3 (c) and CMS4 (d). HRs are adjusted for age, sex and WHO performance status. CAPOX capecitabine
and oxaliplatin, FOLFOX 5-fluorouracil and oxaliplatin, HR hazard ratio. P-values adjusted for multiple testing: 0.96 (a), 0.96 (b), 0.96 (c), 0.08 (d).
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